The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Alzheimer's drug Leqembi (lecanemab) for slowing cognitive decline in patients with mild cognitive impairment or mild dementia. However, the National Institute for Health and Care Excellence (NICE) has deemed the drug too costly for the NHS, citing insufficient long-term effectiveness and high costs associated with treatment and monitoring. This decision leaves the drug available only to those who can afford private care, causing frustration and disappointment among patients and advocates. Charities and experts warn that this situation creates uncertainty and limits access to potentially beneficial treatments for many. Despite the approval, NICE's draft guidance will undergo further consultation before final recommendations are issued.